Fig. 1

Pharmacokinetics of nicotinamide and methyl-nicotinamide in patient plasma and CSF. Red = Treatment, Blue = Placebo. A Each patient’s longitudinal changes in plasma nicotinamide concentration over time. Many data overlap at the minimum of quantification, 0.4 μM. B Average concentration of plasma nicotinamide at 6 months (M6) and 12 months (M12) for drug and placebo recipients. C Each patient’s changes in plasma methyl-nicotinamide concentration over time. D Average concentration of plasma methyl-nicotinamide at 6 and 12 months for drug and placebo recipients. E Each patient’s changes in CSF nicotinamide concentration with treatment. Many data overlap at the minimum of quantification, 0.1 μM. F Average concentration of CSF Nicotinamide at 12 months for drug and placebo recipients. G Each patient’s longitudinal changes in CSF methyl-nicotinamide concentration. H Average concentration of CSF methyl-nicotinamide at 12 months for drug and placebo recipients. Most participants remain at unelevated levels